14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $199.92 $199.92 Thursday, 14th Sep 2023 RXDX stock ended at $199.92. During the day the stock fluctuated 0% from a day low at $199.92 to a day high of $199.92.
90 days $199.92 $199.92
52 weeks $30.75 $199.96

Historical Prometheus Biosciences Inc prices

Date Open High Low Close Volume
Mar 16, 2023 $114.07 $119.71 $113.04 $118.77 604 031
Mar 15, 2023 $115.74 $118.18 $114.43 $115.58 645 801
Mar 14, 2023 $120.00 $123.51 $116.06 $120.00 508 692
Mar 13, 2023 $112.95 $118.55 $111.70 $118.26 551 438
Mar 10, 2023 $118.61 $118.79 $110.04 $114.37 582 418
Mar 09, 2023 $122.50 $123.06 $117.97 $118.99 669 386
Mar 08, 2023 $126.03 $128.59 $125.00 $125.93 364 718
Mar 07, 2023 $123.67 $129.60 $123.20 $126.29 583 575
Mar 06, 2023 $126.10 $126.60 $117.69 $122.55 570 493
Mar 03, 2023 $123.59 $127.28 $122.14 $125.73 417 474
Mar 02, 2023 $121.78 $123.32 $118.30 $123.23 384 771
Mar 01, 2023 $122.85 $125.53 $120.63 $122.02 539 338
Feb 28, 2023 $118.70 $122.80 $118.70 $122.39 324 728
Feb 27, 2023 $117.32 $120.51 $116.11 $118.78 311 188
Feb 24, 2023 $118.76 $121.01 $116.20 $117.10 432 900
Feb 23, 2023 $116.99 $119.12 $115.41 $119.04 323 370
Feb 22, 2023 $121.34 $122.75 $116.24 $116.47 396 077
Feb 21, 2023 $122.07 $122.83 $118.92 $120.70 511 569
Feb 17, 2023 $121.83 $125.65 $120.10 $124.31 632 679
Feb 16, 2023 $121.24 $122.18 $118.00 $120.77 387 918
Feb 15, 2023 $122.20 $122.20 $117.17 $121.01 485 045
Feb 14, 2023 $117.57 $123.69 $115.70 $122.20 638 578
Feb 13, 2023 $117.30 $118.43 $115.20 $117.52 293 763
Feb 10, 2023 $112.38 $118.21 $111.25 $117.51 546 864
Feb 09, 2023 $106.11 $112.68 $105.02 $112.14 573 051
Click to get the best stock tips daily for free!

About Prometheus Biosciences Inc

Prometheus Biosciences Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated ... RXDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT